disulfiram and cisplatin

PreclinicalSmall molecule

FFirst People's Hospital of Hangzhou

disulfiram and cisplatin is one of 42 small molecule programs targeting Gastric Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric CancerActive, not recruiting

Gastric CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

193 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

24 2

Keytruda

Merck & Co.

Phase 3

19 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

55 4

Taxotere

AAvyxa

Phase 3

45 5

Avastin

Roche

Phase 3

11 6

Abraxane

Bristol-Myers Squibb

Phase 3

11 7

Cyramza

Eli Lilly

Phase 3

10 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

20 9

Tuoyi

SSun Yat-sen University

Lynparza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

Treatment of Advance Gastric Cancer With Disulfiram

Not yet recruiting·FFirst People's Hospital of Hangzhou·N/A·NCT05667415·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for disulfiram and cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — disulfiram and cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for disulfiram and cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First People's Hospital of Hangzhou company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFirst People's Hospital of Hangzhou

disulfiram and cisplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News